slides · global inventory
Title
Component collection for the active corpus filters, with each row opening the slide detail view.
Matching slides 303,780
Current window 205,741-205,770
Pages 10,126
Rows per page 30
Component
205,741-205,770 of 303,780
32
Bausch Health Companies | Results Presentation Deck | 48 slidesBausch Health Companies | Results Presentation Deck | 48 slides · Bausch Health
Conference presentation Investor relations 1 hit
33
Includes footnote regarding non-GAAP measures.Bausch Health Companies | Results Presentation Deck | 48 slides · Bausch Health
Conference presentation Investor relations 1 hit
34
Includes Bausch Health logo and page number 34.Bausch Health Companies | Results Presentation Deck | 48 slides · Bausch Health
Conference presentation Investor relations 1 hit
35
Includes detailed breakdown of non-GAAP adjustments and their impact on EPS.Bausch Health Companies | Results Presentation Deck | 48 slides · Bausch Health
Conference presentation Investor relations 1 hit
36
The slide provides a detailed breakdown of adjustments made to GAAP operating income to arrive at non-GAAP adjusted EBITA for two consecutive Q3 periods.Bausch Health Companies | Results Presentation Deck | 48 slides · Bausch Health
Conference presentation Investor relations 1 hit
37
The slide presents two identical table structures for two different time periods.Bausch Health Companies | Results Presentation Deck | 48 slides · Bausch Health
Conference presentation Investor relations 1 hit
38
Includes two separate tables: one for consolidated EBITDA and one for noncontrolling interest adjustments.Bausch Health Companies | Results Presentation Deck | 48 slides · Bausch Health
Conference presentation Investor relations 1 hit
39
Includes footnotes regarding non-GAAP measures, exchange rate impacts, and segment reporting structure.Bausch Health Companies | Results Presentation Deck | 48 slides · Bausch Health
Conference presentation Investor relations 1 hit
40
Includes footnotes regarding non-GAAP measures, exchange rate impacts, and segment reporting changes.Bausch Health Companies | Results Presentation Deck | 48 slides · Bausch Health
Conference presentation Investor relations 1 hit
41
Includes footnote disclosures regarding non-GAAP measures.Bausch Health Companies | Results Presentation Deck | 48 slides · Bausch Health
Conference presentation Investor relations 1 hit
42
Includes adjustments for asset impairments, restructuring, debt extinguishment, and other non-recurring items.Bausch Health Companies | Results Presentation Deck | 48 slides · Bausch Health
Conference presentation Investor relations 1 hit
43
Bausch Health Companies | Results Presentation Deck | 48 slidesBausch Health Companies | Results Presentation Deck | 48 slides · Bausch Health
Conference presentation Investor relations 1 hit
44
Standard financial reporting disclosure slide for non-GAAP reconciliations.Bausch Health Companies | Results Presentation Deck | 48 slides · Bausch Health
Conference presentation Investor relations 1 hit
45
Standard financial disclosure slide explaining non-GAAP adjustments and methodology.Bausch Health Companies | Results Presentation Deck | 48 slides · Bausch Health
Conference presentation Investor relations 1 hit
46
Standard financial disclosure slide for non-GAAP metrics.Bausch Health Companies | Results Presentation Deck | 48 slides · Bausch Health
Conference presentation Investor relations 1 hit
47
Bausch Health Companies | Results Presentation Deck | 48 slidesBausch Health Companies | Results Presentation Deck | 48 slides · Bausch Health
Conference presentation Investor relations 1 hit
48
Bausch Health Companies | Results Presentation Deck | 48 slidesBausch Health Companies | Results Presentation Deck | 48 slides · Bausch Health
Conference presentation Investor relations 1 hit
01
BenevolentAI | Investor Conference Presentation Deck | 17 slidesBenevolentAI | Investor Conference Presentation Deck | 17 slides · BenevolentAI
Conference presentation Investor relations Beat · Problem (Identify pain)1 hit
02
BenevolentAI | Investor Conference Presentation Deck | 17 slidesBenevolentAI | Investor Conference Presentation Deck | 17 slides · BenevolentAI
Conference presentation Investor relations Beat · Problem (Identify pain)1 hit
04
BenevolentAI | Investor Conference Presentation Deck | 17 slidesBenevolentAI | Investor Conference Presentation Deck | 17 slides · BenevolentAI
Conference presentation Investor relations Beat · Problem (Identify pain)1 hit
05
BenevolentAI | Investor Conference Presentation Deck | 17 slidesBenevolentAI | Investor Conference Presentation Deck | 17 slides · BenevolentAI
Conference presentation Investor relations Beat · Agitate (Make it worse)Loop · Cost Of Inaction1 hit
06
The slide uses a split-screen approach to contrast pre-clinical efficiency with clinical efficacy improvements.BenevolentAI | Investor Conference Presentation Deck | 17 slides · BenevolentAI
Conference presentation Investor relations Beat · Agitate (Make it worse)Loop · Cost Of Inaction1 hit
07
The slide uses a process flow diagram to illustrate the company's core technology stack.BenevolentAI | Investor Conference Presentation Deck | 17 slides · BenevolentAI
Conference presentation Investor relations Beat · Agitate (Make it worse)Loop · Cost Of Inaction1 hit
08
Industry benchmarks based on Paul et al Nat Rev Drug Discov 2010.BenevolentAI | Investor Conference Presentation Deck | 17 slides · BenevolentAI
Conference presentation Investor relations Beat · Agitate (Make it worse)Loop · Cost Of Inaction1 hit
09
The chart highlights BenevolentAI's projected productivity (2023-2031) against established industry players.BenevolentAI | Investor Conference Presentation Deck | 17 slides · BenevolentAI
Conference presentation Investor relations Beat · Solution (Provide relief)Loop · Quick Win Big Bet1 hit
10
The slide uses a circular process diagram for the platform and a branching flow for the business model (A, B, C, D).BenevolentAI | Investor Conference Presentation Deck | 17 slides · BenevolentAI
Conference presentation Investor relations Beat · Solution (Provide relief)Loop · Quick Win Big Bet1 hit
11
The chart uses a timeline-like progression (Target ID to Phase III) to visualize drug development stages.BenevolentAI | Investor Conference Presentation Deck | 17 slides · BenevolentAI
Conference presentation Investor relations Beat · Solution (Provide relief)Loop · Quick Win Big Bet1 hit
12
The slide uses a split-layout: left side defines the disease burden and market opportunity, right side defines the drug mechanism and target patient population.BenevolentAI | Investor Conference Presentation Deck | 17 slides · BenevolentAI
Conference presentation Investor relations Beat · Solution (Provide relief)Loop · Quick Win Big Bet1 hit
13
The slide includes explicit caveats regarding the small sample size and short duration of the Phase Ib study.BenevolentAI | Investor Conference Presentation Deck | 17 slides · BenevolentAI
Conference presentation Investor relations Beat · Solution (Provide relief)1 hit
15
The slide uses a list-based structure to demonstrate the efficacy and speed of the AI platform, supported by external validation from The Lancet and Eli Lilly.BenevolentAI | Investor Conference Presentation Deck | 17 slides · BenevolentAI
Conference presentation Investor relations Beat · Solution (Provide relief)1 hit